Intravenous immunoglobulin (IVIg) is used to treat patients with primary antibody deficiencies and, at high doses, to treat a range of autoimmune and inflammatory disorders. With high-dose IVIg (hdIVIg), immunomodulatory mechanisms act on a range of cells, including T cells, B cells, and dendritic cells. Here, we demonstrate that the treatment of M. tuberculosis-infected mice with a single cycle of hdIVIg resulted in substantially reduced bacterial loads in the spleen and lungs when administered at either an early or late stage of infection. Titration of the IVIg showed a clear dose-response effect. There was no reduction in bacterial load when mice were given equimolar doses of another human protein, human serum albumin, or maltose, the stabilizing agent in the IVIg preparation. HdIVIg in vitro had no inhibitory effect on the growth of M. tuberculosis in murine bone marrow-derived macrophages. In addition, the effect of hdIVIg on bacterial loads was not observed in nude mice, suggesting the involvement of conventional T cells. Analysis of T cells infiltrating the lungs revealed only small increases in CD8(+) but not CD4(+) T-cell numbers in hdIVIg-treated mice. The mechanism of action of hdIVIg against tuberculosis in mice rem...Continue Reading
Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis?
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin
Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits.
Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates
Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use
Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein
Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis.
Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model
Human polyspecific immunoglobulin for therapeutic use induces p21/WAF-1 and Bcl-2, which may be responsible for G1 arrest and long-term survival
Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells
Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease
Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses
Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?
Immunogenicity of mycobacterial vesicles in humans: identification of a new tuberculosis antibody biomarker
Vaccination with recombinant Mycobacterium tuberculosis PknD attenuates bacterial dissemination to the brain in guinea pigs
B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response
Vaccines to prevent tuberculosis infection rather than disease: Physiological and immunological aspects
Protective effect of a lipid-based preparation from Mycobacterium smegmatis in a murine model of progressive pulmonary tuberculosis
Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation
The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome
Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis
Intravenous immunoglobulin increases survival time in the acute phase of experimental Chagas disease
Unusual mixed infection of thoracic empyema caused by Mycobacteria tuberculosis, nontuberculosis mycobacteria and Nocardia asteroides in a woman with systemic lupus erythematosus
Adjunct antibody administration with standard treatment reduces relapse rates in a murine tuberculosis model of necrotic granulomas
Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets
Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy
Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis
A pre-term infant of 32 weeks gestation with congenital tuberculosis treated successfully with antituberculosis chemotherapy
Harnessing the Immunomodulatory Properties of Bacterial Ghosts to Boost the Anti-mycobacterial Protective Immunity
A significant therapeutic effect of immunoglobulins administered alone, or in combination with conventional chemotherapy, in experimental pulmonary tuberculosis caused by drug-sensitive or drug-resistant strains
Mycobacterium tuberculosis PPE18 protein inhibits MHC class II antigen presentation and B cell response in mice.
Systematic Evaluation of Mycobacterium tuberculosis Proteins for Antigenic Properties Identifies Rv1485 and Rv1705c as Potential Protective Subunit Vaccine Candidates.
Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.